title: Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
authors.forename: E
authors.initials: E
authors.lastname: Koca
authors.forename: D
authors.initials: D
authors.lastname: Cetiner
authors.forename: H
authors.initials: H
authors.lastname: Goker
authors.forename: S
authors.initials: S
authors.lastname: Aksu
authors.forename: O I
authors.initials: OI
authors.lastname: Ozcebe
authors.forename: I C
authors.initials: IC
authors.lastname: Haznedaroglu
authors.forename: C
authors.initials: C
authors.lastname: Turgan
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology*; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D016030:Kidney Transplantation / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases